Amount of astigmatism and pupil size affect UCVA

Article

Pupil size and the amount of astigmatism affect uncorrected visual acuity (UCVA) in astigmatic eyes, according to an investigation published by the British Journal of Ophthalmology.

Pupil size and the amount of astigmatism affect uncorrected visual acuity (UCVA) in astigmatic eyes, according to an investigation published by the British Journal of Ophthalmology.

Dr Kazutaka Kamiya et al., Department of Ophthalmology, University of Kitasato School of Medicine, Kanagawa, Japan, studied 20 healthy eyes of 20 volunteers. With-the-rule and against-the-rule astigmatism were created after cycloplegic refraction was fully treated. UCVA was measured using artificial pupils of 1 to 5 mm in each eye. To perform a statistical analysis the clinicians used the mean value of three measurements.

Eyes with with-the-rule astigmatism of 1, 2 and 3 D, logMAR UCVA was 0.04±0.08, 0.09±0.09 and 0.16±0.16 for pupils of 1 mm, −0.01±0.09, 0.12±0.15 and 0.33±0.24 for 2 mm pupils, 0.02±0.09, 0.20±0.19 and 0.46±0.30 for 3 mm pupils, 0.02±0.08, 0.24±0.20 and 0.48±0.21 for 4 mm pupils, and 0.08±0.10, 0.33±0.18 and 0.53±0.22 for 5 mm pupils, respectively. Eyes with against-the-rule astigmatism achieved similar results.

The findings advise that, as well as the amount of astigmatism, pupil size should also be considered when improving visual performance in astigmatic eyes.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.